RT Journal Article
SR Electronic
T1 Risk of Suicide Ideation in Comorbid Substance Use Disorder and Major Depression
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.02.28.22271669
DO 10.1101/2022.02.28.22271669
A1 Vivian N. Onaemo
A1 Timothy O. Fawehinmi
A1 Carl D’Arcy
YR 2022
UL http://medrxiv.org/content/early/2022/03/01/2022.02.28.22271669.abstract
AB Background Suicidal behaviour is commonly associated with major depression (MD) and substance use disorders (SUDs). However, there is a paucity of research on risk for suicide ideation among individuals with comorbid SUDs and MD in the general population.Objectives This study investigated the associated risk of suicide ideation in comorbid SUDs - cannabis use disorder (CUD), alcohol use disorder (AUD), drug use disorder (DUD) with depression in a nationally representative sample.Methods Multilevel logistic regression models were used to analyze the 2012 Canadian Community Health Survey (CCHS-MHC) data. This is a cross-sectional survey of nationally representative samples of Canadians (n = 25,113) aged 15 years and older residing in the ten Canadian provinces between January and December 2012. Diagnoses of MD episode, AUD, DUD, CUD, and suicide risk were based on the WHO-CIDI-3.0 derived from DSM-IV diagnostic criteria.Results Comorbidity was found to be the strongest predictor of suicide ideation. Compared to those with no diagnosis, individuals with a comorbid diagnosis of AUD with MDE, CUD with MDE, or DUD with MDE were 9 to 16 times more likely to have suicide ideation. A diagnosis of MDE was a significant predictor of suicide ideation with about a 7-fold increased risk.Conclusion Suicide is a preventable public health issue. Our study found a significantly increased risk of suicide ideation among persons who have comorbid SUD with MD. Effective integration of mental health and addictions services could mitigate the risk of suicide and contribute to better outcomes.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNAFunding StatementThe authors received no specific funding for this workAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.Not ApplicableThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics exemption as it is a secondary analysis of existing dataI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.Not ApplicableI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Not ApplicableI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Not ApplicableAccess to the data is available to bona fide researchers through institutions participating in Statistics Canada Data Liberation Initiative (DLI) including university libraries throughout Canada? see https://www.statcan.gc.ca/eng/dli/dli. Access can be arrange directly through DLI enquiries: statcan.maddlidamidd.statcan@canada.ca.